{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T11:24:52Z","timestamp":1794223492002,"version":"4.8.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Guselkumab is effective in treating moderate-to-severe plaque psoriasis; however, data from randomized controlled trials in the Chinese population are limited. This study evaluated and verified the efficacy and safety profile of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a randomized, double-blind, placebo-controlled, phase 4 study. Patients with moderate-to-severe plaque psoriasis were randomized 2:1 to the guselkumab group (guselkumab 100 mg by subcutaneous injection at weeks 0 and 4, then every 8 weeks thereafter through week 44) or the placebo-to-guselkumab group (placebo at weeks 0, 4, and 12, then guselkumab at weeks 16, 20, 28, 36, and 44). Coprimary efficacy endpoints were the proportion of patients achieving Psoriasis Area and Severity Index (PASI) 90 response and the proportion of patients achieving Investigator\u2019s Global Assessment (IGA) 0\/1 response at week 16.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among the 419 patients screened for eligibility between August 25, 2021, and July 21, 2022, 327 patients were enrolled. All 327 randomized patients (mean age, 41.5 [standard deviation, 12.7] years; 259 [79.2%] men) were treated and included in the analyses. At week 16, 103\/110 patients assigned to the placebo group at baseline started guselkumab treatment. Most patients completed the study (210 in guselkumab group and 101 in placebo-to-guselkumab group). Significantly higher proportions of patients with guselkumab achieved PASI 90 (82.4%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      2.0%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001) and IGA score 0\/1 (88.8%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      7.1%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001) compared with placebo at week 16. At week 48, response rates were maintained in the guselkumab group (PASI 90: 79.2%; IGA 0\/1: 82.4%) and increased in the placebo-to-guselkumab group (PASI 90: 80.2%; IGA 0\/1: 86.3%). During the first 16 weeks, the incidence of adverse events was comparable between groups (41.9% guselkumab\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      39.1% placebo) and the incidence of serious adverse events was low (0.9%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      5.5%), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Guselkumab was highly effective and displayed a favorable safety profile for the treatment of moderate-to-severe plaque psoriasis in Chinese patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT04914429.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003771","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T03:01:00Z","timestamp":1757386860000},"page":"2587-2596","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled trial"],"prefix":"10.1097","volume":"139","author":[{"given":"Kun","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing,400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songmei","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Xi\u2019an Jiaotong University School of Medicine, Xi\u2019an, Shaanxi,710114, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zhejiang Provincial People\u2019s Hospital, Hangzhou, Zhejiang,310011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangdan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Affiliated Hospital of Anhui Medical University School of Medicine, Hefei, Anhui,230022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian,350005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[{"name":"Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital), Guangzhou, Guangdong,510665, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Jiangsu Provincial People\u2019s Hospital, Nanjing, Jiangsu,210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, Hunan,410013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Third Hospital of Peking University, Beijing,100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shandong Dermatological Hospital, Jinan, Shandong,250022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianjin","family":"Lu","sequence":"additional","affiliation":[{"name":"Hospital for Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, Jiangsu,210042, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ruijin Hospital of Shanghai Jiaotong University School of Medicine, Shanghai,200025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Medical University General Hospital, Tianjin,300050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Shi","sequence":"additional","affiliation":[{"name":"Shanghai Skin Disease Hospital, Shanghai,200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang,325000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, West China Hospital, Sichuan University, Chengdu, Sichuan,610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin,300120, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Union Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei,430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoumin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Henan Provincial People\u2019s Hospital, Zhengzhou, Henan,450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Tongren Hospital, Capital Medical University, Beijing,100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang,310016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huashan Hospital, Fudan University, Shanghai,200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan,410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong,518053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Hospital Affiliated to AMU (Southwest Hospital), Chongqing,400038, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beijing,100000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beijing,100000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Shanghai,200233, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Shanghai,200233, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Huang","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Shanghai,200233, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Shanghai,200233, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqi","family":"Dong","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Shanghai,200233, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Lyu","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Shanghai,200233, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang,310006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"R1-20261109","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3390\/biomedicines9111511","article-title":"Psoriasis as an immune-mediated and inflammatory systemic disease: From pathophysiology to novel therapeutic approaches","volume":"9","author":"Campanati","year":"2021","journal-title":"Biomedicines"},{"key":"R2-20261109","article-title":"The global, regional, and national burden of psoriasis: Results and insights from the Global Burden of Disease 2019 study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R3-20261109","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: A systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"R4-20261109","first-page":"426","article-title":"Investigation on the epidemiology of psoriasis in 4 provinces and cities in Southwest China (in Chinese)","volume":"37","author":"Wang","year":"2017","journal-title":"Harbin Med"},{"key":"R5-20261109","first-page":"598","article-title":"An epidemiological survey of psoriasis in six provinces and cities of China (in Chinese)","volume":"24","author":"Ding","year":"2010","journal-title":"Chin J Dermatol Venereol"},{"key":"R6-20261109","first-page":"59","article-title":"Distribution of psoriasis in China: A nationwide screening","volume":"2","author":"Shao","year":"1987","journal-title":"Proc Chin Acad Med Sci Peking Union Med Coll"},{"key":"R7-20261109","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1684\/ejd.2012.1802","article-title":"Prevalence of psoriasis in China: A population-based study in six cities","volume":"22","author":"Ding","year":"2012","journal-title":"Eur J Dermatol"},{"key":"R8-20261109","article-title":"Analysis and contrast of psoriasis disease burden trends in China and globally from 1990 to 2021","volume":"13","author":"Yu","year":"2025","journal-title":"Front Public Health"},{"key":"R9-20261109","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s13555-021-00521-z","article-title":"Scalp psoriasis: A literature review of effective therapies and updated recommendations for practical management","volume":"11","author":"Mosca","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"Suppl 2","key":"R10-20261109","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: Epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R11-20261109","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1097\/CM9.0000000000002563","article-title":"Updates in psoriasis diagnosis and treatment status in China: Results from the National Psoriasis Center Registry","volume":"136","author":"Yang","year":"2023","journal-title":"Chin Med J"},{"key":"R12-20261109","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R13-20261109","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R14-20261109","first-page":"1033","article-title":"Guidelines for the treatment of psoriasis with biologic agents in China","volume":"54","year":"2021","journal-title":"Chin J Dermatol"},{"key":"R15-20261109","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R16-20261109","article-title":"Guselkumab, a novel monoclonal antibody inhibitor of the p19 subunit of IL-23, for psoriatic arthritis and plaque psoriasis: A review of its mechanism, use, and clinical effectiveness","volume":"15","author":"Kerut","year":"2023","journal-title":"Cureus"},{"key":"R17-20261109","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R18-20261109","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R20-20261109","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2340\/00015555-3048","article-title":"The importance of achieving clear or almost clear skin for patients: Results from the Nordic Countries of the Global","volume":"99","author":"Rasmussen","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"R21-20261109","doi-asserted-by":"crossref","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","article-title":"Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis","volume":"34","author":"Chandran","year":"2010","journal-title":"J Autoimmun"},{"key":"R22-20261109","doi-asserted-by":"crossref","first-page":"46381","DOI":"10.18632\/oncotarget.18453","article-title":"Clinic characteristics of psoriasis in China: A nationwide survey in over 12000 patients","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"R23-20261109","first-page":"37","article-title":"Epidemiology and treatment of psoriasis: A Chinese perspective","volume":"4","author":"Pan","year":"2014","journal-title":"Psoriasis (Auckl)"},{"key":"R24-20261109","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/1346-8138.14504","article-title":"Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study","volume":"45","author":"Ohtsuki","year":"2018","journal-title":"J Dermatol"},{"key":"R25-20261109","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09546634.2019.1587145","article-title":"Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study","volume":"31","author":"Ferris","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"R26-20261109","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s13555-021-00523-x","article-title":"Nail psoriasis: A review of effective therapies and recommendations for management","volume":"11","author":"Hadeler","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R27-20261109","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","article-title":"Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: A narrative review","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv Ther"},{"key":"R28-20261109","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40257-021-00612-9","article-title":"Cardiovascular safety of biologics targeting interleukin (IL)-12 and\/or IL-23: What does the evidence say?","volume":"22","author":"de Brito","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"R29-20261109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.670398","article-title":"Adverse events associated with anti-IL-23 agents: Clinical evidence and possible mechanisms","volume":"12","author":"Ru","year":"2021","journal-title":"Front Immunol"},{"key":"R30-20261109","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","article-title":"Long-term safety of guselkumab in patients with psoriatic disease: An integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis","volume":"47","author":"Strober","year":"2024","journal-title":"Drug Saf"},{"key":"R32-20261109","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1097\/CM9.0000000000001232","article-title":"Time to relapse after treatment withdrawal for different biologics used to treat plaque psoriasis","volume":"133","author":"Wang","year":"2020","journal-title":"Chin Med J"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T11:01:03Z","timestamp":1794222063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":30,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003771","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"2024-12-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}